ArticleFrontiers in pharmacology2024
Implementing the EU HTA regulation: Insights from semi-structured interviews on patient expectations, Belgian and European institutional perspectives, and industry outlooks.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic literature review (SLR) on the adoption of artificial intelligence-assisted SLRS: implications for health technology assessments.International journal of technology assessment in health care · 2026Pooled it
- Mapping the Alignment Between the Portuguese Pharmacotherapeutic Assessment Methodology and EU Joint Clinical Assessment Guidance.Therapeutic innovation & regulatory science · 2026Article
- The Post-Authorisation Maze: Mapping of European Pharmaceutical Market Access Pathways in the Early JCA Era.Journal of market access & health policy · 2026Article
- Physicians' Perspectives on Access to Innovative Oncology Therapies: A Cross-Sectional Survey in Bulgaria.Healthcare (Basel, Switzerland) · 2026Article
- The European Union's Health Technology Assessment Regulation (EU-HTA R) Will Prosper Despite Major Setbacks.Journal of market access & health policy · 2026Article
- Epistemological Tensions in the EU HTA Joint Clinical Assessment: The Illusion of Judgment-Free Evaluation.Journal of market access & health policy · 2026Article
- Supporting the Implementation and Addressing the Challenges of the EU HTA Regulation.Journal of market access & health policy · 2026Article
- Competencies for health technology assessment professionals: a scoping review and content analysis.International journal of technology assessment in health care · 2026Article
- Implementing the EU HTA regulation and joint clinical assessment: a multi-stakeholder perspective from Italy.International journal of technology assessment in health care · 2026Article
- Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Level of health technology assessment process-related skills among doctors in Croatia: a cross-sectional survey study.International journal of technology assessment in health care · 2026Article
- Joint Clinical Assessments in Europe: Implications for Market Access, Reimbursement, and National HTA Alignment.Pharmaceutical medicine · 2026Review
- Access to Orphan Medicinal Products in Bulgaria: An Analysis of the Positive Drug List and Individual Access Schemes.Healthcare (Basel, Switzerland) · 2025Article
- Preparing for the EU HTA Regulation: Insights from the Dutch Perspective.Journal of market access & health policy · 2025Article
- Enhancing Patient Engagement in HTA: Using Consensus Research to Overcome PICO Scoping Challenges Under the EU HTAR.Journal of market access & health policy · 2025Article
- Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges.Journal of comparative effectiveness research · 2025Review
- Public Health Decision-Maker Perspective on Joint Clinical Assessments in Central European EU Member States.Journal of market access & health policy · 2025Article
- Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy.Journal of market access & health policy · 2025Article
- A hierarchical and configurational analysis of Health Technology Assessment outcomes for cell and gene therapies.Frontiers in pharmacology · 2025Article
- Artificial Intelligence in Infectious Disease Clinical Practice: An Overview of Gaps, Opportunities, and Limitations.Tropical medicine and infectious disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.